Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,914 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.
Lecchi M, Verderio P, Cappelletti V, De Santis F, Paolini B, Monica M, Sangaletti S, Pupa SM, Iorio MV, Bianchi G, Gennaro M, Fucà G, De Braud F, Tagliabue E, Di Nicola M. Lecchi M, et al. Among authors: bianchi g. Mol Oncol. 2021 May;15(5):1345-1357. doi: 10.1002/1878-0261.12912. Epub 2021 Feb 19. Mol Oncol. 2021. PMID: 33523584 Free PMC article.
Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA.
La Rocca E, De Santis MC, Silvestri M, Ortolan E, Valenti M, Folli S, de Braud FG, Bianchi GV, Scaperrotta GP, Apolone G, Daidone MG, Cappelletti V, Pruneri G, Di Cosimo S. La Rocca E, et al. Among authors: bianchi gv. J Cancer Res Clin Oncol. 2022 Jun;148(6):1543-1550. doi: 10.1007/s00432-022-03990-7. Epub 2022 Apr 9. J Cancer Res Clin Oncol. 2022. PMID: 35396978 Free PMC article.
Mammographic density to predict response to neoadjuvant systemic breast cancer therapy.
Di Cosimo S, Depretto C, Miceli R, Baili P, Ljevar S, Sant M, Cappelletti V, Folli S, Gennaro M, De Braud FG, Bianchi G, Vingiani A, Pruneri G, Marchianò A, La Rocca E, De Santis MC, Scaperrotta GP. Di Cosimo S, et al. Among authors: bianchi g. J Cancer Res Clin Oncol. 2022 Apr;148(4):775-781. doi: 10.1007/s00432-021-03881-3. Epub 2022 Jan 17. J Cancer Res Clin Oncol. 2022. PMID: 35037102
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients.
Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa SM, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: bianchi gv. Ther Adv Med Oncol. 2021 Apr 16;13:17588359211006960. doi: 10.1177/17588359211006960. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33948122 Free PMC article.
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. Triulzi T, et al. Among authors: bianchi gv. Mol Oncol. 2022 Jun;16(12):2355-2366. doi: 10.1002/1878-0261.13141. Epub 2021 Dec 17. Mol Oncol. 2022. PMID: 34816585 Free PMC article.
Prognosis of women with early breast cancer and PIK3CA mutations.
Di Cosimo S, Bianchi GV, Bregni G, de Braud F. Di Cosimo S, et al. Among authors: bianchi gv. Breast. 2015 Jun;24(3):283-4. doi: 10.1016/j.breast.2015.02.028. Epub 2015 Mar 12. Breast. 2015. PMID: 25772325 No abstract available.
1,914 results